Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c

Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $20.63 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
• RETRANSMISSION: Gold Runner Exploration Samples Up To 25,306 Grams per Ton Silver With 11.22 Grams per Ton Gold For a Gold Equivalent of 12.7 Ounces per Ton in New 350 Meter Gold Stack Trend on the 10
• Jones Trading Starts Vogenx (VOGX) at Buy